From: Variability of risk factors and diabetes complications
Risk factor | Type of variability assessed | Short or long term variability | Metrics used | Type of study | Sample size | Significantly associated outcomes | Follow-up length | References |
---|---|---|---|---|---|---|---|---|
Systolic blood pressure | Visit-to-visit | Long-term | Standard deviation | Post-hoc analysis of trial | 9114 | MACE; microvascular outomes | 2.4Â years | [10] |
Post-hoc analysis of trial | 9114 | MACE, renal events, or death; | 7.6Â years | [11] | ||||
Retrospective cohort study | 124105 | Newly developed CVD; all-cause mortality | 39.5Â months | [12] | ||||
Retrospective cohort study | 10163 | Risk of CVD | 24Â months | [13] | ||||
Prospective cohort study | 632 | MACE | 11.3Â years | [14] | ||||
Post-hoc analysis of 2 trials | 2739 | Composite renal outcome | 2.6/3.4Â years | [16] | ||||
Retrospective cohort study | 30851 | Composite renal outcome | 4Â years | [17] | ||||
Coefficient of variation | Post-hoc analysis of 2 trials | 9383 plus 1550 | Heart failure development | 56.6Â months/59.5Â months | [15] | |||
Retrospective cohort study | 10163 | Risk of CVD | 24Â months | [13] | ||||
Retrospective cohort study | 30851 | Composite renal outcome | 4Â years | [17] | ||||
Variation independent of mean | Retrospective cohort study | 10163 | Risk of CVD | 24Â months | [13] | |||
Average real variability | Retrospective cohort study | 10163 | risk of CVD | 24Â months | [13] | |||
Post-hoc analysis of 2 trials | 9383 plus 1550 | Heart failure related event | 56.6Â months/59.5Â months | [15] | ||||
Retrospective cohort study | 30851 | Composite renal outcome | 4Â years | [17] | ||||
Successive variability of measurements | Retrospective cohort study | 10163 | Risk of CVD | 24Â months | [13] | |||
Diastolic blood pressure | Visit-to-visit | Long-term | Coefficient of variation AND Average real variability | Post-hoc analysis of 2 trials | 9383 plus 1550 | Heart failure development | 56.6Â months/59.5Â months | [15] |